| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 13, 2020
LAVAL, QC, and CAMBRIDGE, UK – May 13, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...
-
Mar 22, 2020
Measures taken to safeguard workforce and continuity of operations Recent FDA update on continued efforts to facilitate development of treatments LAVAL, QC and CAMBRIDGE, UK – March 22, 2020 –...
-
Mar 20, 2020
LAVAL, QC and CAMBRIDGE, UK – March 20, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company...
-
Feb 12, 2020
Fibrosis and tissue repair Obesity and non-alcoholic fatty liver disease LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – February 12, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX:LMNL)...
-
Feb 6, 2020
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – February 6, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage...